Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan

Jer Hwa Chang, Jeng Fong Chiou, Ching Sheng Hung, Ming Che Liu, Hui Wen Chang, Shiao Ya Hong, Cheng Yi Wang, Yi Ling Lin, Yi Chen Hsieh, Chi Li Chung, Ying Shih Su, Shu Tai Shen Hsiao, Doresses Liu, Jian Jong Liang, Chun Che Liao, Chih Shin Chang, Kevin Shu Leung Lai, Han Chuan Chuang, Ko Ling Chien, Wei Ciao WuYuan Chii G. Lee, Sey En Lin, Yung Kang Shen, Chiung Fang Hsu, Jude Chu Chun Wang, Shih Hsin Hsiao

研究成果: 雜誌貢獻文章同行評審

摘要

Background: The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. Methods: 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime–boost interval of 8–9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. Results: The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0–147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels (p = 0.035), while female recipients had higher anti-spike IgG levels (p = 0.038). The GMCs of NT50 declined with age (p = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20–29 years, 99.4 IU/mL for ≥50 years, p = 0.0026). Injection-site pain, fever, and fatigue were the major re-actogenicity, which were more pronounced after prime vaccination and in younger participants (<50 years). Platelet counts decreased and D-dimer levels increased after vaccination but were not clinically relevant. No serious adverse events or deaths were observed. Conclusion: The vaccine is well-tolerated and elicited robust humoral immunity against SARS-CoV-2 after standard prime–boost vaccination in Taiwanese recipients.

原文英語
文章編號312
期刊Vaccines
10
發行號2
DOIs
出版狀態已發佈 - 2月 2022

ASJC Scopus subject areas

  • 免疫學
  • 藥理
  • 藥物發現
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan」主題。共同形成了獨特的指紋。

引用此